Merus (MRUS) Stock Forecast & Price Target

Compare

458 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRUS Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Merus

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRUS Stock 12 Month Forecast

Average Price Target

$94.70

▲(72.03%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $94.70 with a high forecast of $110.00 and a low forecast of $67.00. The average price target represents a 72.03% change from the last price of $55.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","111":"$111","56.25":"$56.3","74.5":"$74.5","92.75":"$92.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,56.25,74.5,92.75,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.53,62.48923076923077,66.44846153846154,70.40769230769232,74.36692307692307,78.32615384615384,82.28538461538461,86.24461538461539,90.20384615384616,94.16307692307691,98.12230769230769,102.08153846153846,106.04076923076923,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.53,61.31230769230769,64.09461538461538,66.87692307692308,69.65923076923077,72.44153846153847,75.22384615384615,78.00615384615385,80.78846153846155,83.57076923076923,86.35307692307693,89.13538461538462,91.9176923076923,{"y":94.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.53,59.181538461538466,59.83307692307692,60.48461538461539,61.136153846153846,61.78769230769231,62.43923076923077,63.09076923076923,63.74230769230769,64.39384615384616,65.04538461538462,65.69692307692307,66.34846153846154,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.24,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.45,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.05,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$94.70

Lowest Price Target$67.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$62

Hold

12.62%

Upside

Reiterated

06/05/25

Merus's stock score is bolstered by strong technical momentum and positive corporate events, including successful funding and clinical trials. Financial weaknesses, including persistent losses and cash flow issues, are significant risks. Valuation concerns due to a negative P/E ratio moderate the overall score.

Yigal NochomovitzCiti

Citi

$97→$102

Buy

85.29%

Upside

Reiterated

06/11/25

Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS) and IGM Biosciences (NASDAQ: IGMS)

Tazeen AhmadBank of America Securities

Bank of America Securities

$92

Buy

67.12%

Upside

Reiterated

06/10/25

Merus's Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

Charles ZhuLifeSci Capital

LifeSci Capital

$110

Buy

99.82%

Upside

Reiterated

06/09/25

Underappreciated Potential of Merus's Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

Eva Fortea VerdejoWells Fargo

Wells Fargo

$140→$89

Buy

61.67%

Upside

Reiterated

06/03/25

Wells Fargo Sticks to Their Buy Rating for Merus (MRUS)

Tara BancroftTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/03/25

TD Cowen Sticks to Its Buy Rating for Merus (MRUS)

Michael SchmidtGuggenheim

Guggenheim

$111→$109

Buy

98.00%

Upside

Reiterated

06/02/25

Merus (MRUS) Receives a Buy from Guggenheim

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/02/25

Truist Financial Keeps Their Buy Rating on Merus (MRUS)

Andres Y. MaldonadoH.C. Wainwright

H.C. Wainwright

$85

Buy

54.41%

Upside

Reiterated

05/27/25

H.C. Wainwright Sticks to Their Buy Rating for Merus (MRUS)

Andrew BerensLeerink Partners

Leerink Partners

$88→$95

Buy

72.57%

Upside

Reiterated

05/27/25

Merus (MRUS) Gets a Buy from Leerink Partners

Evan SeigermanBMO Capital

BMO Capital

$96→$110

Buy

99.82%

Upside

Reiterated

05/23/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Merus (NASDAQ: MRUS) and Exelixis (NASDAQ: EXEL)

Ami FadiaNeedham

Needham

$75→$88

Buy

59.85%

Upside

Reiterated

05/23/25

Merus's Peto+Pembro Shows Promising Potential in HNSCC with High Survival Rates and Increased Price Target

John NewmanCanaccord Genuity

Canaccord Genuity

$67

Buy

21.71%

Upside

Reiterated

05/23/25

Promising Developments in Cancer Treatment Drive Buy Rating for Merus with $67 Price Target

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/23/25

Merus's Promising Oncology Advancements Justify Buy Rating Amidst Strong Clinical Results

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

$93

Buy

68.94%

Upside

Reiterated

03/06/25

Stifel Nicolaus Sticks to Its Buy Rating for Merus (MRUS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$62

Hold

12.62%

Upside

Reiterated

06/05/25

Yigal NochomovitzCiti

Citi

$97→$102

Buy

85.29%

Upside

Reiterated

06/11/25

Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS) and IGM Biosciences (NASDAQ: IGMS)

Tazeen AhmadBank of America Securities

Bank of America Securities

$92

Buy

67.12%

Upside

Reiterated

06/10/25

Merus's Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

Charles ZhuLifeSci Capital

LifeSci Capital

$110

Buy

99.82%

Upside

Reiterated

06/09/25

Underappreciated Potential of Merus's Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

Eva Fortea VerdejoWells Fargo

Wells Fargo

$140→$89

Buy

61.67%

Upside

Reiterated

06/03/25

Wells Fargo Sticks to Their Buy Rating for Merus (MRUS)

Tara BancroftTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/03/25

TD Cowen Sticks to Its Buy Rating for Merus (MRUS)

Michael SchmidtGuggenheim

Guggenheim

$111→$109

Buy

98.00%

Upside

Reiterated

06/02/25

Merus (MRUS) Receives a Buy from Guggenheim

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/02/25

Truist Financial Keeps Their Buy Rating on Merus (MRUS)

Andres Y. MaldonadoH.C. Wainwright

H.C. Wainwright

$85

Buy

54.41%

Upside

Reiterated

05/27/25

H.C. Wainwright Sticks to Their Buy Rating for Merus (MRUS)

Andrew BerensLeerink Partners

Leerink Partners

$88→$95

Buy

72.57%

Upside

Reiterated

05/27/25

Merus (MRUS) Gets a Buy from Leerink Partners

Evan SeigermanBMO Capital

BMO Capital

$96→$110

Buy

99.82%

Upside

Reiterated

05/23/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Merus (NASDAQ: MRUS) and Exelixis (NASDAQ: EXEL)

Ami FadiaNeedham

Needham

$75→$88

Buy

59.85%

Upside

Reiterated

05/23/25

Merus's Peto+Pembro Shows Promising Potential in HNSCC with High Survival Rates and Increased Price Target

John NewmanCanaccord Genuity

Canaccord Genuity

$67

Buy

21.71%

Upside

Reiterated

05/23/25

Promising Developments in Cancer Treatment Drive Buy Rating for Merus with $67 Price Target

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/23/25

Merus's Promising Oncology Advancements Justify Buy Rating Amidst Strong Clinical Results

Bradley CaninoStifel Nicolaus

Stifel Nicolaus

$93

Buy

68.94%

Upside

Reiterated

03/06/25

Stifel Nicolaus Sticks to Its Buy Rating for Merus (MRUS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merus

1 Month

xxx

Success Rate

10/18 ratings generated profit

Average Return

+1.49%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +1.49% per trade.

3 Months

xxx

Success Rate

10/13 ratings generated profit

Average Return

+19.46%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +19.46% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

15/18 ratings generated profit

Average Return

+30.38%

reiterated a buy rating 4 days ago

Copying Charles Zhu's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +30.38% per trade.

2 Years

xxx

Success Rate

26/27 ratings generated profit

Average Return

+86.19%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.30% of your transactions generating a profit, with an average return of +86.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRUS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRUS has received 45 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MRUS average Analyst price target in the past 3 months is 94.70.

Each month's total comprises the sum of three months' worth of ratings.

MRUS Financial Forecast

MRUS Earnings Forecast

Next quarter’s earnings estimate for MRUS is -$1.16 with a range of -$1.49 to -$0.93. The previous quarter’s EPS was -$1.40. MRUS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year MRUS has Outperformed its overall industry.

MRUS Sales Forecast

Next quarter’s sales forecast for MRUS is $10.45M with a range of $2.97M to $26.80M. The previous quarter’s sales results were $26.49M. MRUS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year MRUS has Outperformed its overall industry.

MRUS Stock Forecast FAQ

What is MRUS’s average 12-month price target, according to analysts?

Based on analyst ratings, Merus NV’s 12-month average price target is 94.70.

What is MRUS’s upside potential, based on the analysts’ average price target?

Merus NV has 72.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRUS a Buy, Sell or Hold?

Merus NV has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Merus NV’s price target?

The average price target for Merus NV is 94.70. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $67.00. The average price target represents 72.03% Increase from the current price of $55.05.

What do analysts say about Merus NV?

Merus NV’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of MRUS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Merus (MRUS) Stock Forecast & Price Target

MRUS Analyst Ratings

MRUS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merus

MRUS Analyst Recommendation Trends

MRUS Financial Forecast

MRUS Earnings Forecast

MRUS Sales Forecast

MRUS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts